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Abstract 
Interactions of malignant multiple myeloma (MM) plasma cells (MM-cells) with the 
microenvironment control MM-cell growth, survival, drug-resistance and dissemination. As in MM 
microvascular density increases in the bone marrow (BM), we investigated whether BM MM 
endothelial cells (MMECs) control disease progression via the junctional adhesion molecule A 
(JAM-A). Membrane and cytoplasmic JAM-A levels were upregulated in MMECs in 111 newly 
diagnosed (NDMM) and 201 relapsed-refractory (RRMM) patients compared to monoclonal 
gammopathy of undetermined significance (MGUS) and healthy controls. Elevated membrane 
expression of JAM-A on MMECs predicted poor clinical outcome. Mechanistically, addition of 
recombinant JAM-A to MMECs increased angiogenesis whereas its inhibition impaired 
angiogenesis and MM growth in 2D and 3D in vitro cell culture and chorioallantoic membrane-
assays. To corroborate these findings, we treated MM bearing mice with JAM-A blocking mAb and 
demonstrated impaired MM progression corresponding to decreased MM-related vascularity. 
These findings support JAM-A as an important mediator of MM progression through facilitating 
MM-associated angiogenesis. Collectively, elevated JAM-A expression on bone marrow 
endothelial cells is an independent prognostic factor for patient survival in both NDMM and RRMM. 
Blocking JAM-A restricts angiogenesis in vitro, in embrio and in vivo and represents a suitable 
druggable molecule to halt neoangiogenesis and MM progression. 
 3
 
Introduction 
Junctional adhesion molecule-A (JAM-A), also known as JAM-1, CD321, F11R, belongs to the 
immunoglobulin superfamily.1 In healthy tissues, JAM-A regulates cell growth and differentiation, 
while its aberrant expression or deregulation confers a more aggressive phenotype with poor 
prognosis in different types of human cancers1, including multiple myeloma (MM)2, breast, lung, 
brain and head and neck cancer.3 
JAM-A over-activation results either from upregulation or aberrant dimerization, driving the 
receptor in a state of constitutive signal transmission, or from excessive release of JAM-A ligands 
by normal and tumor cells into the microenvironment.4 Membrane-bound JAM-A and its soluble 
form (sJAM-A) can form homophilic interactions and also heterophilic interactions1 with lymphocyte 
function-associated antigen 1 (LFA-1), afadin (AFDN), calcium/calmodulin-dependent serine 
protein kinase (CASK) and tight junction protein-1 (TJP1) with high receptor/ligand binding 
affinities.5 These interactions trigger JAM-A downstream signaling pathways involved in the 
regulation of tumor cell survival, growth, angiogenesis and dissemination.6 
JAM-A inhibition can be achieved by direct blocking of both the ligand-binding site on the 
extracellular receptor domain with monoclonal antibodies (mAb)7 and indirectly with small-molecule 
inhibitors.8 Moreover, neutralizing the sJAM-A9 released into the microenvironment can prevent 
JAM-A activation.10  
JAM-A plays a pivotal role in endothelial cell physiology6 and pathology.2 Although JAM-A function 
in tumorigenesis has been investigated in solid tumors3, and its angiogenic role has been shown in 
pancreatic islet carcinoma11, data on JAM-A related angiogenesis in hematologic neoplasms 
remains elusive. Since BM neovascularization favors MM progression12, we investigated whether 
JAM-A can drive angiogenesis in MM13 contributing to MM disease progression.2  
We quantified JAM-A surface expression on 312 MM patient’s BM-derived endothelial cells 
(MMECs) and demonstrated that JAM-Ahigh MMECs strongly correlate with poor survival both in 
newly diagnosed (NDMM) and relapsed/refractory (RRMM) patients. Mechanistically, adding 
recombinant JAM-A protein to MM-cells increased angiogenesis in both 2D and 3D models. 
Conversely, blocking JAM-A impaired MM related angiogenesis. To corroborate these findings, we 
treated MM bearing mice with JAM-A blocking mAb and observed impaired MM progression and 
decreased MM vascularity.  
 
Methods 
Patients  
Patients fulfilling the International Myeloma Working Group diagnostic criteria14 for NDMM (n=111), 
relapsed/refractory patients15 (RRMM) (n=201) and monoclonal gammopathy of undetermined 
significance (MGUS) (n=35) were included in this study. Patient characteristics and genetics risk 
stratification are provided in Supplementary Table 1 and 2. The study was approved by the 
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Ethical Committee of the Bari and Würzburg University Hospitals (reference number 5145 and 
76/13), and all patients provided their informed consent following the Declaration of Helsinki, 
(detailed in Supplementary Methods). 
 
Cell lines and cultures procedures 
RPMI-8226, OPM-2 and HUVECs cells were cultured as described.3 MM-cells were co-cultured 
with MMECs (4 × 105) at a 1:1 and 1:5 cell ratios for 24 hours with or without an inserted transwell 
(0.4 μm pore size; Costar, Cambridge, MA, USA) (detailed in Supplementary Methods).  
 
Chick chorioallantoic membrane (CAM) assay 
Fertilized chicken eggs were incubated at 37°C at constant humidity. On day 8, sterilized gelatin 
sponges adsorbed with MMECs conditioned medium (CM) or medium obtained by treatment of 
MMECs with sJAM-A (100 ng/mL), with or without α-JAM-A mAb were implanted on the top of the 
CAM (detailed in Supplementary Methods).  
 
MM xenograft mouse models  
Twenty female 8- to 10-week-old NOD.CB17-Prkdcscid/NCrHsd mice (NOD-SCID, Envigo, 
Huntingdon, UK) were injected intratibially with 2 × 105 RPMI-8226 cells suspended in PBS. Mice 
were treated with the α-JAM-A mAb (Sigma-Aldrich, St. Louis, MO, USA, mouse monoclonal clone 
J10.4) recognizing the distal membrane extracellular domain of JAM-A. 
Twenty female 6- to 8-week-old NOD-SCID mice were injected subcutaneously (s.c.) into the right-
hand flank with 1 × 107 RPMI-8226 cells suspended in 200 μL RPMI-1640 medium and 200 μL 
MatrigelTM as described16 (detailed in Supplementary Methods).  
 
Functional in vitro assays 
Wound-healing and MatrigelTM angiogenesis assays were performed as previously described 
(detailed in Supplementary Methods).  
 
Protein expression studies and Reverse transcriptase PCR, real-time RT-PCR  
Western blot, ELISA, human angiogenesis array real-time RT-PCR were performed according to 
manufacturer’s instructions (detailed in Supplementary Methods). 
 
Immunohistochemistry 
Details are supplied in Supplementary Methods. 
 
In silico analysis from the CoMMpass study dataset 
Details are supplied in Supplementary Methods. 
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Statistical analysis 
Descriptive analysis was carried out using median and interquartile range for the quantitative 
variables and percentages values for the qualitative ones. 
Normality distribution was tested using the Shapiro-Wilk test. Membrane MMECs JAM-A 
expression levels (mean fluorescence intensity - MFI obtained in FACS) were dichotomized into 
two classes, JAM-Ahigh/low, choosing the median as class boundary (detailed in Supplementary 
Methods). Moreover, for further confirmatory survival analysis quartile ranges based model has 
been implemented (detailed in Supplementary Methods).  
 
Results  
Elevated JAM-A expression on BM primary MMECs correlates with poor prognosis in both 
NDMM and RRMM 
First, we compared the JAM-A expression in MMECs and MGECs (Figure 1A). JAM-A mRNA 
expression in MMECs significantly exceeded JAM levels in MGECs (1.8 fold-change, P<.0001) 
and of healthy endothelial cells (Supplementary Figure 1A). Subsequent Western Blot (WB) 
analysis confirmed that MMECs significantly upregulated JAM-A protein expression in comparison 
to MGECs (P<.0001, Figure 1B).  
Because JAM-A had proven as a prominent adhesion molecule on MM cells previously2 and is also 
known to form homophilic interactions1, we investigated whether JAM-A expression on the 
vascular microenvironment affects disease outcome. To this end, we enrolled 312 patients, 111 
with newly diagnosed MM (NDMM) and 201 with relapsed/refractory (RRMM) disease. Employing 
flow cytometry on MMECs we divided newly diagnosed MM patients based on JAM-Ahigh and JAM-
Alow MMEC surface expression (Figure 1C). Immunohistochemical analyses of BM trephines 
corroborated these findings (Figure 1D, Supplementary Figure 1B, C). Notably, OS was 
significantly shorter in patients with JAM-Ahigh MMECs than in patients with JAM-Alow MMECs 
(Figure 1E upper panel) [JAM-Ahigh MMEC group median not reached (NR) vs. JAM-Alow MMEC 
group 78 months (hazards ratio-HR=9.14, 95% CI 2.8–29.76), P<.001; χ2LR=20.11; P<.0001]. 
Strikingly, these results maintained significant also in the multivariate analysis (HR=9.11, 95% CI 
2.79–29.76), P <.001) (Figure 1E lower panel); concerning the PFS, only the renal impairment 
displayed a significant impact in univariate as well as in multivariate analysis (HR=1.64, 95% CI 
1.09–2.47, P=.017); MMECs JAM-A expression levels did not influence risk of progression in 
NDMM (data not shown). Thus, JAM-A overexpression on MMECs represents a risk factor for a 
shorter OS in NDMM. 
Next, we interrogated a 201 RRMM cohort with flow cytometry. Within these relapsed/refractory 
patients, JAM-Ahigh MMECs represented an independent poor prognostic factor for OS and also for 
PFS (Figure 2A-B). Survival differed significantly in patients with JAM-Ahigh MMECs: the median 
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OS was 130 months in patients with JAM-Ahigh MMECs and not reached yet in those with JAM-Alow 
MMECs (Figure 2A, HR=2.96, 95% CI 1.36–6.37, P<.006; χ2LR=8.52; P=.0035). 
In patients with JAM-Alow MMECs cells, the median PFS estimated was 27 months, while, in 
subjects with JAM-Ahigh MMECs the median PFS reached only 18.3 months (Figure 2B, HR=1.41, 
95% CI 1.05-1.88; P=.019; χ2LR=5.78; P=.0162). 
Multivariate analyses confirmed JAM-Ahigh MMECs as an independent significant risk factor for low 
OS (HR=2.39, 95% CI 1.09–5.28; P=.030) in much the same way were for R-ISS stage II 
(HR=5.34, 95% CI 1.24–22.97; P=.024) and III (HR=.57, 95% CI 1.25–34.54; P=.026) and chronic 
kidney disease (HR=2.12, 95% CI 1.00–4.52; P=.049) (Figure 2C). Cox stratified model 
implemented for PFS confirmed only high levels of membrane MMECs JAM-A as a statistically 
significant risk factor (HR=1.35, 95% CI 1.00–1.81; P=.044) stratified by chronic kidney disease 
(Figure 2C).  
Interestingly, only the JAM-Ahigh MMECs kept significance in the multivariate model. Moreover, we 
found a significant association in RRMM setting between JAM-Ahigh MMECs and the R-ISS stage II 
and III (χ2=17.4, P<.0001) and the risk of extramedullary dissemination (χ2=7.04, P=.008). Thus, 
JAM-A surface expression on BM endothelial cells derived from MM patients exerted a strong and 
independent effect with a linear trajectory concerning OS impacted in both cohorts and an additive 
poor prognostic impact on PFS in the RRMM cohort. Additionally, we dissected the entire cohort 
(Supplementary Figure 1D) in quartile ranges of MMECs’ surface expression and then compared 
the lowest (JAM-AQ1) to the highest one (JAM-AQ4). Strikingly, OS differed significantly in subjects 
from the JAM-AQ4: the median OS was 88 months in JAM-A Q4 patients and was not reached in 
JAM-AQ1 patients (HR=8.24, 95% CI 3.2–20.9, P<.0001; χ2LR=28.15; P<.0001). Interestingly, JAM-
AQ4 MMECs kept significance in the multivariate Cox-model (HR=6.36, 95% CI 2.3–17.63; P<.001). 
This comparison further corroborated JAM-A positive vs. negative MMECs role in predicting poor 
clinical outcome in our cohort (Supplementary Figure 1E, upper and lower panels). The 
absence of a statistically significant impact on NDMM PFS is likely due to a more pronounced 
effect of JAM-A MMEC-expression in a more advanced MM stage. This suggests the importance 
of JAM-A within the BM microenvironment during disease progression. 
 
MMECs enhance the JAM-A expression on MM-cells. 
To address how interactions with MMECs functionally influence MM cell biology, we performed 
indirect and direct co-culture experiments of MMECs with MM-cell lines. JAM-A expression levels 
increased on MM-cells when co-cultured with MMECs (Figure 3A, B). We next exposed MM-cells 
to primary MMECs- or MGECs-derived culture media, respectively. Again, the JAM-A protein 
expression increased on MM-cells after exposure to MMECs medium compared to MGECs 
medium (Figure 3C and D, respectively). Results confirmed JAM-A upregulation upon direct co-
culture experiments (Supplementary Figure 2A). Notably, only after direct co-culture MMECs 
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recapitulated the same behavior of MM-cells (Supplementary Figure 2B). Consistently, also 
soluble JAM-A (sJAM-A) levels increased after co-culture of MM with MMECs cells 
(Supplementary Figure 2C). Similar to RPMI-8226 cells, OPM-2 cells upregulated JAM-A after 
direct co-culture with MMECs (Supplementary Figure 2D), but not after indirect culture (data not 
shown). These data indicate that both cell-cell contact and soluble factors released by MMECs into 
the BM microenvironment upregulated JAM-A expression on MM-cells. MMECs JAM-A 
upregulation parallels this dynamic process, suggesting a vicious cycle, promoting MM growth by 
supporting angiogenesis.  
 
JAM-A enhances angiogenesis in 2D and 3D conditions 
We hypothesized that JAM-A upregulation during MM progression may enhance angiogenesis. To 
this end, we treated MMECs with increasing concentrations of human recombinant sJAM-A and 
measured different parameters17 of angiogenesis.18 To examine whether JAM-A directly affects 
spontaneous MMEC-migration, we performed experiments in 2D and 3D environments. Enhanced 
spontaneous MMECs migration was observed after 12 hours of sJAM-A treatment in a 2D scratch 
assay by counting migrating MMECs (Figure 4A, upper and lower panel). Blocking α-JAM-A 
abolished the enhanced MMECs migration (Figure 4A, upper panel) and reduced migrating 
MMECs numbers (Figure 4A, lower panel). In a 2D angiogenesis assay, sJAM-A treatment 
increased the endothelial structure complexity in terms of branching points and vessel lengths as 
angiogenesis parameters. Three hours after seeding, sJAM-A treatment resulted in a structured 
capillary network, while the control remained in a rudimentary stage of organization with small 
clumps of cells distributed on the MatrigelTM layer (Figure 4B, upper left quadrant). Furthermore, 
we tested the effect of JAM-A inhibition in MMECs by both siRNA and blocking α-JAM-A without 
adding sJAM-A (Figure 4B, lower left and upper right quadrants, respectively). Consistently, 
blocking JAM-A with a mAb impaired the capillary network formation and resulted in poorly 
skeletonized structures (Figure 4B, lower right quadrant). The observed down-modulation of 
MMEC migration, reduced number of branching points and vessel length occurred independent of 
cytotoxic effects, since JAM-A-neutralization did not affect MMEC survival (Supplementary Figure 
3A, left and right panels). 
Based on the 2D observations, we investigated whether JAM-A would influence structured MM-
associated angiogenesis in a 3D CAM assay. CAMs were implanted with gelatin sponges loaded 
with either MMECs conditioned-medium as control (CTRL) or MMECs conditioned medium with 
sJAM-A (+sJAM-A), in presence or absence of a blocking α-JAM-A mAb. MMECs conditioned-
medium stimulated new vessel formation in CAM19 that was profoundly enhanced by adding sJAM-
A. This effect could be selectively inhibited by treatment with a sJAM-A blocking antibody as 
treatment with a cocktail containing an isotype IgG1 control antibody (sJAM-A + ISO, middle panel) 
did not reduce vessel formation (Figure 4C).  
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To explore potential factors that enhance JAM-A mediated MM angiogenesis, we compared 
conditioned media from MMECs supplemented with sJAM-A before and after α-JAM-A treatment 
with an angiogenesis array (Figure 4D and Supplementary Figure 3B). sJAM-A strongly reduced 
anti-angiogenic and increased pro-angiogenic factors secreted by MMECs16 such as plasminogen 
(PLG), fibroblast growth factor2 (FGF-2), insulin-like growth factor binding protein1 (IGFBP1) and 
vascular endothelial growth factors A and C (VEGFA, VEGFC). RT-PCR corroborated the 
proteomic findings and revealed sJAM-A-induced transcriptional upregulation of these factors and 
ligands (PLG and ENO1, JAM-A with LFA-1 and TJP1) (Supplementary Figure 3C-L). Moreover, 
because JAM-A can form homophilic interactions with JAM-A itself1 as well as heterophilic 
interactions with LFA-1, TJP1, CAV1 and CASK, we investigated whether the expression of these 
ligands correlated with MM-MMECs interactions. Direct co-culture of RPMI-8226 and MMECs 
significantly increased LFA-1, CAV1 on MM-cells, whereas TJP1, CASK and ADAM17 expression 
levels decreased (Supplementary Figure 3G-K). Therefore, we tested if the induced gene 
expression was non-random, by testing further molecules involved in neoplastic angiogenesis 
processes12, namely VEGFA, VEGFC, HGF, FGF16 and Aurora Kinase A (AURKA)20; also in this 
case we found a significant VEGFA and AURKA gene up-regulation after MM-MMEC co-culture 
(Supplementary Figure 3F, L). 
These data support that MM-MMEC interactions enhance angiogenesis. Thus, we asked whether 
MM cells actively participate to the angiogenesis program in a reciprocal interaction with the BM 
microenvironment in patients and investigated if a pro-angiogenic gene-signature can detect 
patients with worse PFS and OS. Therefore, we interrogated 646 NDMM patients enrolled in the 
CoMMpass trial, comparing two different cohorts, based on survival outcome (alive vs. dead for 
OS and progressed vs. ongoing for PFS) performing a supervised analysis based on the gene 
expression of the pro-angiogenic factors contained in the angiogenesis array and other well-known 
JAM-A interactors. Strikingly, these two cohorts differed significantly: JAM-A, ENO-1, VEGFA and 
AURKA were all overexpressed in patients experiencing a shorter PFS and OS. Conversely, 
reduced TJP1 expression in patients correlated with poor survival (Supplementary Table 3). 
These gene expression data confirmed the protein expression results from our patient cohort. 
Exogenous JAM-A modulated the secretory profile of MMECs favoring angiogenesis and highlights 
the tight connection with an angiogenic environment, comprising key angiogenic factors, such as 
PLG, FGF-2, IGFBP1, VEGFA and VEGFC. 
 
JAM-A inhibition impairs angiogenesis and inhibits tumor growth in vivo   
To investigate whether JAM-A inhibition may affect in vivo angiogenesis and in turn MM-cell 
growth, we employed two different mouse models. To mimic advanced MM21 we injected RPMI-
8226 cells intratibially in NOD-SCID mice and analyzed bone specimens after α-JAM-A treatment.2 
Blocking JAM-A reduced MM cell proliferation and angiogenesis (Figure 5A). This difference 
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deemed statistically significant regarding numbers and percentage of Ki-67high proliferating MM-
cells (79.87 ± 1,242 and 35.38 ± 0,3455 in the ISO Control and in the α-JAM-A-treated group, 
respectively, P<.0001) and vessels/mm2 field (9.3 and 7.1 in the ISO Control and in the α-JAM-A-
treated group, respectively P<.0001) (Figure 5B). Also, the α-JAM-A treated group expressed 
lower JAM-A levels (79.78 ± 1,443 and 36.98 ± 0,466 in the ISO Control and in the α-JAM-A-
treated group respectively P<.0001), lower CD31% (5.58 ± 1,34 and 3.48 ± 0,646 in the ISO 
Control and in the α-JAM-A-treated group, respectively P<.0001) and displayed a lower vessel 
density (calculated as vascular number/mm2) than in the ISO Control, which presented a greater 
number of vessels with well-lit lumina (9.77 ± 2,63 and 6.48 ± 0,631 ISO Control vs. α-JAM-A-
treated group, P<.0001). 
To assess the activity of the anti-JAM-A blocking antibody on angiogenesis on a solitary 
plasmacytoma in vivo and to non-invasively monitor the MM cells growth at extraosseous sites with 
a caliper, we employed a subcutaneous MM xenograft model. This approach allows to dissect the 
endothelial bystander effect on BM-independent extramedullary MM.21 Thus, we employed a 
second in vivo xenograft model engrafting RPMI-8226 cells s.c. into the flanks of NOD/SCID 
mice.21 Animals were randomized at day three after engraftment and mice were treated either with 
α-JAM-A mAb or with a non-specific isotype control antibody i.p. for three days/week for 40 days. 
Subsequently, we measured the vascular area, the tumor volume and the hemoglobin content of 
the MM mass. Blocking α-JAM-A reduced the vascular area in the soft tissue MM masses in 
comparison to ISO Controls (difference between median -0.015, P<.0001). No adverse events 
occurred upon continuous α-JAM-A treatment.  
Notably, after 40 days, the vascular area significantly increased in tumors and MM disease 
progressed more in controls compared to the α-JAM-A-treated group (Figure 6A, CD31 staining 
and 6B). In ISO Control-treated mice, tumors grew exponentially contrasting only reduced tumor 
growth in α-JAM-A-treated animals (Figure 6B and Supplementary Figure 4A). Lower 
hemoglobin content confirmed poor MM vascularization in the α-JAM-A-treated mice (8.4 ± 0.04 in 
ISO Control vs. 5.5 ± 0.04 in α-JAM-A-treated group, P <.0001, C.I. -3.02 to -2.8, Figure 6C). Ki-
67-staining, vascular area and vessel count confirmed that blocking JAM-A strongly reduced the 
MM vascularity and disease progression. Furthermore, JAM-A blocking significantly reduced 
proangiogenic factors such as FGF-2 and VEGF-A in the peripheral blood plasma of MM bearing 
mice (Supplementary Figure 4B-D). 
 
Discussion  
The angiogenic switch is a key process during transition from premalignant asymptomatic 
MGUS to full-blown MM. The evaluation of angiogenic parameters in the BM at the time of 
diagnosis was widely considered as a predictive factor for MM progression.22 In solid tumors, 
such as breast, lung, head and neck and brain cancers, JAM-A activation promotes tumor 
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progression, while its inhibition by anti-JAM-A2 agents reduces tumor growth.11 We 
demonstrated in four independent experimental settings that JAM-A essentially stimulates MM-
associated angiogenesis. In the CAM assay, a neutralizing α-JAM-A mAb caused strong 
reduction of the number of vessels, implying that JAM-A exerts an essential angiogenic stimulus 
that could not be replaced by any other compensating factor contained in the MMECs CM.23 Our 
new findings pinpoint JAM-A as an attractive target in MM patients. JAM-A appears pivotal in 
MM evolution, which can be explained by several angiogenic mechanisms.24,25 First, we 
demonstrated significantly increased JAM-A levels on MMECs from NDMM patients compared 
to MGECs. Furthermore, we could link the high JAM-A surface expression on MMECs with a 
significantly shorter OS in both ND- and RRMM and, at even more advanced disease stages, 
higher JAM-A expression levels correlated also with reduced PFS. Therefore, we examined the 
pathophysiologic basis responsible for favoring MM progression. As already described for 
HGF/cMET axis26,27, JAM-A acts within the BM microenvironment, sustaining the neoplastic 
clone and promoting MM related angiogenesis both with direct and indirectly priming MMECs. 
Thus, JAM-A and its soluble isoform sJAM-A appear to feed into a vicious cycle involving the 
MMECs in generating a malignant environment favorable for MM progression. Although JAM-A 
is expressed in several solid cancers3, to our knowledge this is the first report of endothelial 
JAM-A expression in its role for the MM tumor microenvironment. Homophilic interactions 
between recombinant sJAM-A and membrane JAM-A have been demonstrated biochemically.10 
Homophilic JAM-A interactions can be inhibited with an α-JAM-A mAb that binds to an epitope 
close to the N-terminus of the mature protein10 as well as by a peptide that corresponds to the N-
terminal 23 residues of the mature protein.28 This suggests that the homophilic trans-interaction 
is mediated through the membrane-distal V-type Ig-like JAM-A domain at the N-terminus of the 
molecule. Targeting this domain of the JAM-A molecule on MMECs in our in vitro co-culture 
systems suggests that this type of interaction mediated the MM-MMEC crosstalk. In line with 
previous reports about MMECs sustaining MM growth29,30, our disease models showed that 
during the transition from the pre- to the angiogenic phase, proliferation of tumor cells and 
neovascularization intensely involve over-expression of JAM-A on MMECs. MMECs were 
responsive to the presence of sJAM-A in the surrounding microenvironment, which increased 
their JAM-A surface protein expression. sJAM-A directly and indirectly upregulated JAM-A on 
the bystander MM-cells, independent from their basic JAM-A expression status. These 
observations support that cellular components of MM BM, including MMECs, can release JAM-A 
to sustain disease progression and prepare a tumor "friendly" niche, exerting significant 
modulation on FGF-2, VEGF-A and PLG/ENO1 downstream effect.  
JAM-A has been described to interact with CD9, a well-known driver of MM-related drug 
resistance31 and clinical prognosis.32 We found a significant expression of FGF-2, a potent 
stabilizer and activator of a ternary complex involving JAM-A, CD9 and αvβ3 integrin, a novel 
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potential therapeutic target.33 Peddibhotla et al. described that the aggregation of this ternary 
complex can activate downstream pathway cascades to induce proliferation, migration and an 
angiogenic stimulus to endothelial cells.34 Our in silico validation shed more light on this 
pathophysiological process. ENO-1, encoding for the cytoplasmic α-Enolase, works as a 
plasminogen receptor and its up-regulated membrane expression is described in several cancer 
types.35,36 Of note, plasminogen up-regulation had been correlated with tumor invasion and 
angiogenesis37; its activation, derived by the interaction with α-Enolase, prompted an activation 
of downstream signaling such as the MEK-ERK pathway, able to further promote cell invasion 
and angiogenesis. α-Enolase can also modulate the anti-tumor immune response. Cappello et 
al., described that α-Enolasehigh myeloid-derived-suppressor-cells (MDSCs) could not adhere to 
TNFα primed endothelial cells in presence of an anti-ENO-1 mAb. Consequently, a decreased 
MDSC migration reduced the in situ immunosuppression enhancing the T cell-mediated 
immunity against malignant cells.38,39  
We found that JAM-A overexpression in MMECs strongly correlated with ADAMTS1, a regulator 
of angiogenesis40 and immune-surveillance41, which appears to play a central role in preparing a 
favorable BM milieu.42 We also identified that JAM-A surface expression on MMECs inversely 
correlated with ADAM17 expression. Conversely, sJAM-A release, directly correlated with 
ADAM17 upregulation, a mechanism described for endothelial cells in inflammation.9 ADAM17 
upregulation has been also observed in MM in the context of fractalkine release43, which 
highlights this system as a potential novel therapeutic target in MM patients to disrupt a vicious 
circle formation enhancing the MM niche.  
JAM-A also strongly correlated with AURKA in MM patients. This finding may link JAM-A 
mediated cell-adhesion to MM resilience and drug resistance.20 Indeed, proteasome engulfment 
derived proteotoxicity44 and invasiveness through epithelial-mesenchymal-transition and cell-
adhesion45 confer complex biological events that affect prognosis.46 We also demonstrated that 
the interaction between MMECs and MM-cells affects JAM-A and other fundamental molecules, 
such as TJP1 and LFA-1 expression. This reciprocal “education” parallels the invasive attitude of 
the MM-cells towards the endothelial counterpart, instructing the vasculature to actively interact 
with the malignant cells, potentially driving their survival and drug resistance.47,48 In line with this, 
increased JAM-A endothelial levels strongly correlated with unfavorable and resistant MM 
stages such as high R-ISS disease stages and the risk of extramedullary development. 
An interaction network of JAM-A and α-Enolase49 emphasizes the strong communication with 
the MM niche environment to allow persistence and sustaining proliferative signaling. Therefore, 
JAM-A may represent a key factor in the nurturing soil50 to support MM evolution. Moschetta et 
al.13 previously described the endothelium-MM-cells interdependency: EPCs trafficking 
enhances MM progression, particularly at an early disease stage. Rajkumar et al. highlighted a 
progressive increase in BM angiogenesis along the spectrum of plasma cell disorders from 
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MGUS to advanced MM.12 Integrating the prognostic relevance of JAM-A expressed by MMECs 
and our experimental data prompts us to propose JAM-A as a key player in coordinating the 
interactions with the MM milieu enabling a permissive BM ecosystem during the aggressive 
disease evolution from NDMM to RRMM. 
Indeed, the anti-MM effect of the JAM-A blocking also relies on its complex relationship with 
antiangiogenic effect, especially in critical transition phases of MM progression, such as the 
passage through MGUS to symptomatic MM and from responsive to drug-refractory disease, 
interfering with a main proangiogenic factor and with MM-cell proliferation. Our 2D and 3D models 
showed that mechanistically, JAM-A drives MM-associated angiogenesis via homophilic interaction 
and through identified downstream targets, namely FGF2, VEGF-A and PLG/ENO1, in the BM 
microenvironment. Moreover, the clinical impact demonstrated on a large cohort of consecutive 
individuals pinpoint JAM-A axis as a new player in the MM-associated angiogenesis able to better 
stratify patient’s prognosis, especially in more advanced disease.  
Collectively, the close link between MM and the BM microenvironment appears paradigmatic for 
MM evolution and disease progression. We connected the interaction of MMECs with MM-cells via 
the adhesion molecule JAM-A. Our data point towards a vicious cycle of JAM-A overexpression on 
MMECs mirrored in a higher JAM-A expression on the tumoral counterpart. Shed from the cell 
surface, sJAM-A enhances homophilic JAM-A complex establishment fostering MM niche 
formation. Finally, our results may open the development of JAM-A based therapeutic strategies 
directed against MM-interactions with the tumor microenvironment (Figure 7A-D). Clearly, these 
findings need to be confirmed in a larger patient population in a carefully designed prospective 
clinical study. 
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Figure legends 
 
Figure 1. Elevated JAM-A expression on BM primary MM endothelial cells (MMECs) in newly 
diagnosed patients (NDMM) correlates with poor OS. (A) Relative mRNA expression level of 
JAM-A of MMECs compared to MGECs by RT real time-PCR (n=73 MGUS patients derived 
MGECs and 73 NDMM derived MMECs), **** P< 0.0001, Mann-Whitney test. (B) Western Blot 
densitometric analysis of basal protein expression of JAM-A of MGECs and MMECs lysates 
normalized to β-actin (n=24 MGUS patients derived MGECs and 24 NDMM derived MMECs). 
Results are presented as mean ± SD, **** P< 0.0001, Mann-Whitney test. (C) FACS analysis of 
JAM-A cell surface expression from representative patient-derived MMECs, identified as 
CD45/138/38neg/31pos cells. (D) JAM-A overexpression colocalizes with a higher vessel density on 
bone marrow biopsies. Vessel density (as highlighted by CD34 [red] staining) was higher in bone 
marrow spaces infiltrated by JAM-Ahigh (brown) neoplastic plasma cells, as compared to JAM-Alow 
cases. Magnification x 200. Scale bar=50 μm (E) Kaplan-Meier estimator of OS, by level of surface 
MMECs JAM-A expression. The median OS estimated in subjects with JAM-Alow MMECs cells at 
FACS was not reached whereas in subjects with JAM-Ahigh MMECs the median OS was 78 months 
(HR= 9.14, 95% CI 2.8–29.76, P< 0.0001; χ2LR=20.11; P< 0.0001, upper panel). Uni- and 
multivariate analysis (lower panel). BM: bone marrow; MGECs: MGUS derived endothelial cells; 
NDMM: newly diagnosed MM; Pts: patients. OS: overall survival; NR: not reached. R-ISS: Revised 
International Staging System; Hb: hemoglobin. 
 
Figure 2. Elevated JAM-A expression on bone marrow primary MM endothelial cells 
(MMECs) predicts poor prognosis in relapsed refractory multiple myeloma (RRMM). Kaplan-
Meier estimator of OS (A) and PFS (B), by level of surface MMECs JAM-A expression. (C) Cox 
model - set on OS and PFS analyses. The median follow-up was 53 months (4–262 months) for 
OS and 23 months (1–119 months) for PFS. *Cox models adjusted for sex and age. **Cox 
stratified hazards regression by chronic kidney disease. OS: overall survival; PFS: progression free 
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survival; MMECs: bone marrow primary MM endothelial cells. Pts: patients. NR: not reached. R-
ISS: Revised International Staging System; Hb: hemoglobin. 
 
Figure 3. BM primary MM endothelial cells (MMECs) enhance JAM-A expression on MM-
cells. Experimental designs depicted at the top. RPMI-8226 cells have been cultured alone or co-
cultured with MMECs at 1:5 ratio (RPMI-8266:MMECs) in inserted transwells and analyzed for 
JAM-A expression with Western blot (A) and flow cytometry (B). (C) RPMI-8226 cells were 
maintained for 24 hours in conditioned media from MMECs or MGECs. Cells were harvested and 
lysed and the extracted proteins immunoblotted for JAM-A expression. Overall densitometric 
analyses are reported. (D) RPMI-8226 cells were also analyzed at FACS after culture for 24 hours 
in MGECs or MMECs CM. Results are presented as mean ± SD, (n=24 MGUS patients derived 
MGECs and 24 NDMM derived MMECs), P< 0.0001 ****, Mann-Whitney test. BM: bone marrow; 
MGECs: MGUS derived endothelial cells; NDMM: newly diagnosed MM; CM: conditioned medium; 
MFI: mean fluorescence intensity.  
 
Figure 4. Pivotal role of JAM-A in MM associated angiogenesis in 2D and 3D conditions. (A) 
Upper panel. Confluent monolayers of MMECs underwent a scratch wound-healing assay. 3 hours 
after scratching photographs were taken of MMECs that had been maintained in MMECs CM 
alone (CTRL) or previously supplemented for 12 hours with sJAM-A at 100 ng/mL and added 
isotype control (+sJAM-A +ISO) or α-JAM-A (+sJAM-A +α-JAM-A) blocking antibody. Lower panel: 
Migrating cells in each wound were counted. Counts of proliferating and migrating cells of six 
independent experiments. **** P< 0.0001, Mann-Whitney test. (B) Photographs at 3 hours of 
newly-formed capillary networks after MMECs were seeded on MatrigelTM layer. Direct comparison 
of MMECs in CM vs. MMECs treated with 100 ng/ml sJAM-A (upper left panel). Independent 
experiment to assess JAM-A inhibition in MMECs either treated with an anti-JAM-A blocking 
antibody vs. isotype control antibody (upper right panel). Independent experiment to assess JAM-A 
knock-down in MMECs comparing treatment with JAM-A specific siRNA vs. non-specific 
scrambled siRNA without addition of sJAM-A (lower left panel). Independent experiment to assess 
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the effect of blocking JAM-A after addition 100 ng/ml of sJAM-A by comparing capillary formation 
after MMECs treatment with sJAM-A and anti-JAM-A blocking antibody vs. sJAM-A and isotype 
control antibody (lower right quadrant). Representative pictures of three biological replicates. 
Skeletonization of the meshes were analyzed and branching points measured. Data are 
normalized to control. Scale bar=100 μm. (C) Chorioallantoic membrane assay with the gelatin 
sponge loaded with MMECs CM alone (CTRL) or with MMECs CM supplemented with sJAM-A 
(+sJAM-A), in presence or absence of 0,5 µg/ml α-JAM-A mAb. On day 12, pictures were taken in 
ovo. One representative experiment is shown at 50X magnification. Newly formed vessels were 
counted. Mann-Whitney test. (D) An array of 55 human angiogenesis related proteins was 
performed on MMECs CM after sJAM-A treatment without and with blocking with the α-JAM-A 
mAb. Array spots were analyzed with ImageJ Lab v. 1.51 software and normalized to positive 
control signal intensities. Graph bars represent the pixel density of the detected angiogenesis-
related cytokines in two independent experiments. Values are expressed as mean ± SD of ten 
independent experiments.  Mann-Whitney test. * P< 0.05; and **** P< 0.0001, versus SFM as 
control. See Supplementary Figure 3 and the main text for more details. MMECs: bone marrow 
primary MM endothelial cells; CM: conditioned medium; CTRL: control; SFM: serum free medium; 
n.s.= not significant. CAM: Chick chorioallantoic membrane. 
 
Figure 5. JAM-A inhibition reduces MM proliferation and vasculature in intratibial MM in 
vivo model. NOD/SCID mice (n= 20) bearing RPMI-8226 intratibial xenograft were repetitiously 
treated with α-JAM-A blocking mAb, or isotope control IgG (ISO) for three weeks. (A) Upper panel. 
From left to the right. Ki67/CD138 and JAM-A staining: CD138 and JAM-A (red) reactivity appears 
to be more represented on the smaller neoplastic plasma cells, whereas the most 
pleomorphic/anaplastic component shows lower reactivity; a reverse staining distribution is 
observed for Ki67 nuclear staining (brown), which is more prominent on the larger cells. 
CD31/JAM-A double and CD31 coloration (brown) highlights endothelia lining thin walled 
microvessels; lumina appear to be only slightly dilated; JAM-A (red) stains a fraction of neoplastic 
plasma cells, with a cytoplasmic pattern. Lower panel. Decreased Ki67 expression in α-JAM-A 
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derived specimen. Within the CD31 stained noninvolved BM lacunae (see CD31+ megakaryocytes) 
from the α-JAM-A treated group the vessels are more distended, and endothelia display a thin, 
inconspicuous cytoplasmic rim. (B) From left to the right, differences in terms of MM proliferation, 
JAM-A, CD31 positivity on endothelial cells and vessels count, assessed by two pathologists. Data 
shown are mean ± SD from ten individual mice for each group. **** P< .0001 versus controls, 
obtained with Mann-Whitney test. Scale bar=100 μm. BM: bone marrow. 
 
Figure 6. JAM-A inhibition restricts angiogenesis and tumor growth in subcutaneous MM 
xenograft model. NOD/SCID mice (n= 20) bearing RPMI-8226 subcutaneous xenograft were 
repetitiously treated with α-JAM-A blocking mAb, or isotope control IgG (ISO) or with vehicle only 
for 40 days for 3 days/week. (A) Immunohistochemistry staining: JAM-A (red) reactivity is higher in 
the smaller neoplastic cells whereas in most pleomorphic/anaplastic components it is lower. A 
reverse staining distribution is observed for Ki67 nuclear staining (brown), which is more clear-cut 
in the larger cells. CD31 staining shows focal positivity in the control group and it is absent in the 
α-JAM-A group. (B) Treatment was continued for three days a week for 40 days and tumor 
volumes were measured every two days with a caliper. (C) Hemoglobin values, Ki-67 positivity, 
vessel area and number of vessels expressed as mean ± SD of three independent experiments. 
*P< 0.05 versus vehicle-treated control. Scale bar=50 μm.****P< .0001 versus controls obtained 
with Mann-Whitney test. 
 
Figure 7. JAM-A boosts MM-related angiogenesis in the BM microenvironment. (A) Molecular 
interactions between MM-cells and MMECs: cell-adhesion mediated changes via trans-
homo/heterophilic JAM-A interaction. (B) FGF-2 mediates pro-angiogenic and proliferative role of 
JAM-A and its release as monomeric JAM-A from the ternary complex through an unknown 
mechanism. We speculate that once monomeric JAM-A is available at a membrane level, it forms 
homodimers that mediate downstream signaling and is also susceptible for cleavage and shedding 
via ADAM17. (C) JAM-A mediated cytoskeleton rearrangement via TJP1 down regulation and cell 
function modification: depending on myeloma cells-mediated interactions the endothelial cells can 
lose their tight junction and be prone to increase the vascular permeability. (D) PLG/ENO1 
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interaction triggers angiogenesis and microenvironment modification via JAM-A. Caveolin1 
modulates the transport of cytosolic ENO-1 to the cell surface. BM: bone marrow; MMECs: bone 
marrow primary MM endothelial cells; FGF-2: Fibroblast growth factor-2; ADAM17: ADAM 
metallopeptidase domain 17; TJP1: Tight junction protein-1; PLG: plasminogen; ENO1: Enolase 1; 
LFA-1: Lymphocyte function-associated antigen 1; MAPK: mitogen-activated protein kinase; αVβ3: 
Integrin alpha V beta 3; CD9: CD9 Molecule; VEGFA: Vascular Endothelial Growth Factor A; 
ADAMTS1: Human Metalloproteinase with Thrombospondin Type 1 Motifs. AURKA: Aurora Kinase 
A. See results and discussion for additional details.  
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Supplementary Methods 
Patients derived cells and MMECs isolation 
Bone marrow (BM) primary endothelial cells from MM (MMECs) and MGUS (MGECs) patients were 
obtained and cultured as described.1,2 Full BM blood served as source for MMECs identification. 
Endothelial cells were harvested by magnetic cell sorting with anti-CD31 micro-beads (Miltenyi 
Biotech, Hamburg, Germany) from adherent mononuclear cells cultured for three weeks as 
described.2,3 
The NDMM patient cohort (70 male and 41 female), ages 60 to 73 (median 67 years) were newly 
diagnosed with MM.4 The monoclonal (M) component was IgG (n=64), IgA (n=27), IgM (n=1) and 
k or l (n=12). The MGUS patients (23 male and 12 female), ages 42 to 79 (median 60.5 years), 
were IgG (n=20), IgA (n=8) and k or l (n=7). The validation cohort was composed of 201 
relapsed/refractory patients (RRMM) defined as previously described5 129 male and 72 female), 
ages 54 to 69 (median 62 years) whose M component was IgG (n=124), IgA (n=58), IgM (n=3), IgD 
(n=2), k or l (n=13) and biclonal (n=1). 
 
Cell separation and cultures procedures  
BM mononuclear cells (BMMoCs) were obtained by centrifugation on Ficoll-Hypaque gradient of 
heparinized bone marrow (BM) aspirates1 and maintained in Roswell Park Memorial Institute 
medium (RPMI)-1640 supplemented with 10% FBS. After seven days, media were collected and 
JAM-A measured by ELISA. MMECs were isolated from BMMoCs using anti-CD31 MACS beads 
(Miltenyi Biotech, Hamburg, Germany). Purified MMECs and MGECs were grown and expanded for 
four passages in fibronectin coated culture dishes (BD Falcon, Küsnacht, Switzerland) in endothelial 
basal medium (EBM-2 Lonza, Basel, Switzerland) supplemented with 5% FBS with 10ng/ml VEGF 
(Miltenyi Biotech, Hamburg, Germany) as previously described.2,3  Cell population purity (>95%) was 
determined with a FACSCanto II flow cytometry system (Becton Dickinson-BD, San Jose, CA, USA). 
In functional studies, MMECs were used until the 6th passage of culture, in DMEM supplemented 
with 10% FBS, 2mMol L-Glutamine, 100U/ml Penicillin, 100µg/ml Streptomycin (Sigma-Aldrich, St. 
Louis, MO, USA). Human RPMI-8266 MM-cells were maintained in RPMI-1640 supplemented with 
10% FBS and routinely tested to exclude mycoplasma contamination. To obtain MMECs conditioned 
media, MMECs were grown to 80% confluence in serum-free DMEM medium for 24 hours. Culture 
media, antibiotic/antimycotic, glutamine, trypsin/EDTA, and PBS without Ca2+ and Mg2+ were all 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
MGECs, MMECs and MM-PCs were obtained from BM aspirates. MM-PCs were identified as the 
CD138+ population within the gate of live cells. MM-PCs, MM-cell lines (RPMI-8226 and OPM-2) and 
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HUVECs were stained with an anti-JAM-A antibody (anti-JAM-A FITC, clone OV5B8 (BioLegend, 
San Diego, CA, USA). Full marrow blood was stained with anti-CD31 (WM-59, Thermo-Fisher, 
Waltham, Massachusetts, USA), anti-CD45 (HI30, Thermo-Fisher, Waltham, Massachusetts, USA) 
and anti-CD138 (MI15, BioLegend San Diego, CA, USA) and endothelial cells recognized from BM 
mononuclear cells as CD45 negative, CD138 negative, CD31 positive within the living population. 
Human RPMI-8226 and OPM-2 myeloma cell lines were obtained from the American Type Culture 
Collection (ATCC; Rockville, MD, USA), and cultured according to the manufacturer’s instructions. 
MMECs, RPMI-8226 and OPM-2 cells were harvested for western blot, co-culture and FACS 
experiments. MMECs co-cultured with RPMI-8266 or OPM-2 cells were separated by 
immunoselection. Culture media were collected and analyzed with ELISA and an angiogenesis array 
(R&D Systems®, Minneapolis, Minnesota, USA). MMECs were immunomagnetically separated with 
anti-CD31 MACS beads (Miltenyi Biotech, Bergisch Gladbach, Germany). 
 
Reverse transcriptase PCR, real-time RT-PCR 
Isolated mRNA was reverse transcribed into cDNA with the iScript cDNA Synthesis Kit (Bio-Rad, 
Hercules, CA, USA). The mean of JAM-A mRNA expression levels in MGECs or in HUVECs were 
used as reference values and GAPDH as housekeeping gene. Real-time PCR was performed using 
the “StepOne real-time RT-PCR system” (Applied Biosystems, Foster City, CA, USA). Relative 
quantification of the mRNA level was evaluated using the comparative Ct method with 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as reference gene and with the 2−ΔΔCT 
formula. qRT-PCR TaqMan probes were from Applied Biosystems (Waltham, MA, USA). Primer 
sequences are available in Supplementary Table 4. Total RNA from MMECs and MGECs was 
extracted using the RNeasy Mini kit (Qiagen, Milano, Italy) and the real-time was performed 
according to manufacturer’s instructions. 
 
Immunostaining and labeling of human tissues and cells 
Consecutive sections of specimens with confluent plasma cell infiltrates were stained with the 
following antibodies: anti-CD138 (MI15, Dako Agilent, Waldbronn, Germany) and CD31 (ab76533, 
Abcam, Cambridge, UK), according to the manufacturer’s instructions. Slides were evaluated by an 
experienced hemato-pathologist. 
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Wound-healing assay 
The wound-healing assay was performed as previously described6. In short, MMECs were grown 
until confluence on fibronectin-coated (10 mg/mL) 12 well plate and the "wound" was generated by 
scraping the cell monolayer with a P200 pipette tip. Cells were exposed to serum free medium (SFM) 
alone or admixed with increasing concentrations of human sJAM-A (100 ng/mL). MMECs were also 
treated with 100 µg/ml neutralizing/blocking a-JAM-A mAb (10µg/mL, clone J10.4, Sigma-Aldrich, 
St. Louis, MO, USA). Afterward cells were fixed with 4% paraformaldehyde and stained with crystal 
violet. The migrating MMECs were counted in 3 different fields of the wound area at X10 
magnification with EVOS digital inverted microscope (Euroclone, Pero, MI, Italy). Cell viability was 
determined using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, USA) 
according to the manufacturer’s instructions.  
 
Matrigel angiogenesis assay 
As the homophilic interaction between sJAM-A and the native transmembrane JAM-A had been 
demonstrated7,8, a MatrigelTM angiogenesis assay was done by placing the MMECs on MatrigelTM-
coated plates.9 Pictures of the skeletonized topological parameters "mesh areas", "branching points" 
and "vessel length" of the angiogenic network were measured by two independent observers using 
a computerized image analyzer10 and ImageJ software.11 
Matrigel (Becton Dickinson-BD, San Jose, CA, USA) 48-well plates in MMECs-derived conditioned 
medium (CTRL) alone or supplemented with increasing concentrations of the soluble recombinant 
human JAM-A (sJAM-A), up to 100 ng/mL, (Human JAM-A/F11R Protein, Sino Biological, Beijing, 
PRC). MMECs were also plated in CTRL in presence of 0.5 μg/mL neutralizing/blocking a-JAM-A 
mAb. Pictures were acquired in three randomly chosen fields with an EVOS microscope. 
 
Western blot  
Total MMECs and MGECs protein lysates were quantified with the Bradford assay (Bio-Rad, 
Hercules, CA, USA) and subjected to immunoblot with primary and secondary antibodies to the 
following: JAM-A (cod. 4267, Sigma-Aldrich, St. Louis, MO, USA) mAb; JAM-AmAb (clone OV-5B8, 
BioLegend San Diego, CA, USA) beta-actin (cod. A1978, Sigma-Aldrich); and mouse and rabbit 
horseradish peroxidase–conjugated IgG (Bio-Rad). Immunoreactive bands were visualized by 
enhanced chemiluminescence (SuperSignal West Femto Maximum Sensitivity Substrate, Thermo 
Fisher Scientific, Waltham, MA, USA) with Gel Logic 1500 Imaging System (Eastman Kodak Co.). 
Bands were quantified using Kodak Molecular Imaging Software and expressed as arbitrary optical 
density (OD). 
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ELISA 
Supernatants from MMECs alone or co-cultured with MM-cells were analyzed with ELISA to detect 
sJAM-A concentrations using a Human JAM-A ELISA Kit (R&D Systems, Minneapolis, MN, USA) 
following the manufacturer’s instructions. 
 
Chorioallantoic membrane assay (CAM)  
Fertilized white Leghorn chicken eggs were incubated at 37°C at constant humidity. On day 3, the 
shell were opened and 2 to 3 mL of albumen were removed to detach the chorioallantoic membrane 
(CAM). On the 8th day, the CAMs were implanted with 1 mm3 sterilized gelatin sponges (Gelfoam, 
Upjohn Co, MI, USA) filled with SFM alone or with 100 ng/mL of sJAM-A, or with MMECs conditioned 
medium (MMECs CM) in presence or absence of 100 μg/mL of neutralizing/blocking a-JAM-A mAb, 
or with medium of sJAM-A-treated MMECs (JAM-A CM) with or without neutralizing/blocking anti-
JAM-A mAb. On the 12th day, blood vessels entering the sponges within the focal plane of the CAMs 
were counted and pictures taken in embrio at X50 (Olympus stereomicroscope). 
CAMs were examined daily until day 12 and photographed in ovo with a stereomicroscope. Vessels 
entering the sponges within the focal plane of the CAM were counted by two observers in a double-
blind fashion at 50x magnification and confirmed by ImageJ software.11,12 
 
In vivo experiments and immunohistochemistry on mice tissues 
Intratibial xenograft MM model 
Twenty mice were treated with a-JAM-A mAb (Sigma-Aldrich, St. Louis, MO, USA, mouse 
monoclonal clone J10.4, 5 mg/kg body weight in 100 μL PBS) or with an isotype control. The 
administration schedule was three times per week on days 1, 4, 6, 8, 11, 13, 15 and 18. Mice were 
euthanized for histology on day 22 after MM-cell injection. 
Subcutaneous xenograft MM model 
Twenty mice (10/groups) were randomized to intraperitoneal (i.p.) a-JAM-A mAb (Sigma-Aldrich, St. 
Louis, MO, USA, mouse monoclonal clone J10.4) 5mg/kg body weight (in 100 μL PBS), or with an 
isotype control (mouse IgG polyclonal antibody 12–371) three days/week for 40 days. Tumor growth 
was measured twice weekly, and weights (mg=mm3) calculated as the length (mm) × width2 (mm2)/2. 
Mice were sacrificed when the tumor weight reached ∼2.5 g.  
The isotype control utilized for MM xenograft model was obtained from Merck Millipore, Darmstadt, 
Germany. 
Immunohistochemical analysis followed mAb binding was visualized using 3,3’Diaminobenzidine 
(DAB) as a chromogenic substrate. After deparaffinization and rehydration, the BM biopsy slides 
were placed in a pressure cooker in 0.01M citrate buffer (pH 6.1, DAKO, Hamburg, Germany) and 
heated for 3 min. Incubation with anti-JAM-A mAb (clone J3F.1, Santa Cruz, Dallas, TX, USA) was 
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carried out at room temperature for 1 hour. Detection was performed with the DAKO Advance system 
according to the manufacturer’s protocol. BM involvement was assessed as the percentage of 
positive cells relative to the total cell count (for example 40% of nuclear cells). Bone marrow sections 
and subcutaneous extramedullary tumors were single or double stained for Ki67 (LS-C175347, 
LifeSpan BioSciences, Seattle, WA, USA), CD138 (LS-B9360, LifeSpan BioSciences, Seattle, WA, 
USA), JAM-A (clone J3F.1, Santa Cruz, Dallas, TX, USA), CD31 (ab76533, abcam, Cambridge, UK) 
and CD34 (QBEND10 clone, Abcam, Cambridge, UK), according to the manufacturer’s instructions. 
JAM-A staining was performed by incubating samples with anti-JAM-A mAb at room temperature for 
1 hour. Detection was performed with the DAKO Advance system according to the manufacturer’s 
protocol, using DAB and Magenta chromogens. BM involvement was assessed as the percentage 
of positive cells relative to the total cell count (for example 40% of nuclear cells); Ki67 was assessed 
as the mean of 5 counts of 100 cells, from separate fields; vessel density was evaluated as number 
of CD31+ vascular structures per mm2. Stained bone marrow sections were analyzed by two 
experienced hemato-pathologists with a Zeiss Axioskop 40 microscope equipped with a Zeiss 
AxioCam MRc digital camera. 
Mice were housed according to the Institutional Animal Care and Use Committee of the University 
Medical School of Bari, following guidelines published by Kilkenny et al.13 Clinical signs of toxicity 
were monitored daily, while body weight was measured twice weekly.14 
Immunohistochemical analysis of the mouse BM or subcutaneous mass specimens was performed 
with a specific antibody against JAM-A as described. Hemoglobin content of each plug was 
measured using Drabkin’s assay (Sigma Aldrich, St. Louis, MO, USA) and normalized to its 
weight.14,15  Specifically, the angiogenesis quantification in the subcutaneous xenograft model was 
also performed by the hemoglobin content evaluation, a well-established tool used to assess vessel 
density in xenograft Matrigel sponge tumor models: in detail, assay aliquots of 50 µl of reconstituted 
complete medium, containing 50 U/ml heparin, are added to unpolymerized Matrigel at 4°C at a final 
volume of 0.6 ml. The Matrigel suspension was injected subcutaneously into the flanks of mice by 
using a cold syringe. At body temperature, the Matrigel polymerized to a solid gel, which became 
vascularized within 4-7 days in response to angiogenic substances. Pellets were removed at the end 
of the experiment, photographed, minced, and diluted in water to measure the hemoglobin content 
with a Drabkin reagent kit (Sigma-Aldrich, St. Louis, MO, USA)914,16. 
 
Measurement of cytokines and angiogenic factors 
Before starting the treatment, peripheral blood samples from 20 mice were collected into EDTA-
containing tubes before treatment initiation and one day before mice were euthanized. Plasma was 
separated by centrifugation (2,000 rpm for 20 min at 4 °C) within 1 h from blood drawing and 
aliquoted into multiple cryovials. Plasma samples were stored at − 80 °C until use. Before analysis, 
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plasma samples were thawed slowly in an ice bath and all analyses were done from a one-off thaw 
sample. Cytokine and angiogenic factor (CAFs) were measured by using Q-Plex™ Array Human 
Angiogenesis Antigen (Quansys Biosciences, Logan, Utah) allowing the simultaneous quantification 
of the following factors: angiopoietin-2 (ANG-2), fibroblast growth factor-2 (FGF-2), hepatocyte 
growth factor (HGF), interleukin-8 (IL-8), platelet-derived growth factor-BB (PDGF-BB), tissue 
inhibitor of matrix metalloproteinase-1 and 2 (TIMP-1, TIMP-2), tumor necrosis factor-alpha (TNF-
α), and vascular endothelial growth factor (VEGFA), according to the manufacturer’s instructions. 
Secreted levels of CAFs were quantified through Q-View Software (Quansys Biosciences, Logan, 
Utah) in triplicate samples, and the mean results were used in biomarker analysis. 
 
Human angiogenesis array 
MMECs were cultured in SFM with or without 100 ng/ml sJAM-A for 24 hours and media were 
collected and concentrated to be analyzed by Human Angiogenesis Array kit (R&D Systems®, 
Minneapolis, Minnesota, USA) according to the manufacturer’s instructions. Spots were quantified 
with ImageJ 5.1 Software (Bio-Rad) and values were reported as mean pixel density. 
 
In silico analysis  
For further validation in a larger NDMM patient cohort, the public data set from the CoMMpass19 
longitudinal, prospective observational study (release IA12) was interrogated, provided by the 
Multiple Myeloma Research Foundation and downloaded from (https://research.mmrf.org). Two 
patient subgroups were considered, relapsed/progressed or died versus ongoing for PFS and died 
versus alive for OS. In detail, a supervised analysis was performed including 125 genes known to 
be prognostically relevant in MM, either due to GEP phenotyping17 or angiogenetic pathway related 
signature.18 
The public CoMMpass data set from the RNAseq data from 646 NDMM patients was analyzed and 
the cohort stratified depending on the outcome (progression-free survival - PFS and overall survival 
- OS status). Expression profiles in patients were compared who progressed or died in comparison 
with patients who did not. The dataset interrogation and the relative clinical information analysis were 
generated as part of the Multiple Myeloma Research Foundation Personalized Medicine Initiative. 
 
Statistical analysis 
The compiled clinical data forms, together with the recoded variables, were inserted into a database 
built with Office Excel software and analyzed with Stata SE15 software. The median value of the 
variable obtained in FACS of the mean fluorescence intensity (MFI) for the expression of the JAM-
A surface was used as a cutting point to recode the latter as a categorical variable (JAM-Ahigh/low): 
Solimando et al.                 Supplementary Material 
 7 
the highest values equal to the median of 989 were classified as JAM-Ahigh, the lowest values as 
JAM-Alow. 
Kaplan–Meier curves were used to show progression-free survival (PFS) and overall survival (OS) 
related to higher levels of surface JAM-A expression, and log-rank were determined to evaluate the 
differences. PFS refers to the time elapsed from the date of enrollment in this study and the date of 
relapse, disease progression or death, determined from the last follow-up visit. OS refers to the time 
elapsed from the date of enrollment in this study and date of death from any cause. Given the 
population characteristics for NDMM cohort, the scanty number of failure events we could not 
perform a multivariate analysis for OS. Despite the significant impact on PFS at univariate analysis 
none of the covariates maintained a relevant effect in the implemented multivariate model (data not 
shown). 
For RRMM cohort univariate and multivariate Cox proportional hazard models were performed to 
detect significant predictors (covariates chosen on the basis of the statistical significance (univariate 
analysis, P≤.05) and of the clinical judgment; age and sex were used as adjusting variables) for OS 
and PFS in the patient cohort. The model applicability assumption was evaluated by the Schoenfeld 
test. The collinearity between the nominal covariates was tested using the Cramér's V measure. For 
the covariates that did not satisfy the hypothesis of proportional hazards we proceeded with stratified 
Cox model (with interaction and with no interaction including the Likelihood Ratio Test used to 
estimate model parameters). Applying the same statistical methodology, we also implemented an 
additional analysis by dividing the continuous MMECs JAM-A MFI values by quartile ranges across 
the entire cohort (n=312).  
In vitro, in embrio and in vivo experimental results were expressed as individual data or as the mean 
± SD and analyzed using Wilcoxon signed-rank test, Mann-Whitney U test and One-Way Anova test. 
Statistical analysis was performed using GraphPad Prism6 software (La Jolla, CA, USA). Analysis 
performed on the in silico data was conducted using t-test and fold change. 
For in vivo experiments, sample size was calculated using G*Power software version 3.1.9.2 (power 
of 80% and 0.05 statistical level). Assuming an effect-size of 0.4 with statistical significance of a <.05 
and a power of 80%. Values <.05 deemed as statistically significant. Statistical analyses were 
performed with STATA/SE for Windows, version 15. 
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Supplementary Tables  
Supplementary Table 1. 
Patients characteristics, NDMM cohort. 
Variable N. patients (%) Median Values 
Median Age 111/111 (100) 67 years (60 - 73) 
Sex 
Male: 
Female:  
111/111 (100) 
70/111 (63) 
41/111 (37) 
 
R-ISS 
Stage I  
Stage II 
Stage III 
111/111 (100) 
23/111 (20.7) 
65/111 (58.6) 
23/111 (20.7) 
 
Type of MM 
IgG 
IgA 
IgM 
Light chain 
104/111 (93.7) 
64/104 (61.5) 
27/104 (26) 
1/104 (1) 
12/104 (11.5) 
 
Genetic risk*: 
Standard risk: 
High risk: 
106/111 (95) 
57/106 (53.8) 
49/106 (46.2) 
 
 
Hemoglobin 
Hb <10 g/dL 
110/111 (99) 
51/110 (46.3) 
10.2 g/dL (9 – 11.8) 
 
Kidney failure 
Yes: 
No: 
107/111 (96.3) 
49/107 (45.8) 
58/107 (54.2) 
 
Bone lesions 
Yes: 
No: 
111/111 (100) 
78/111 (70.3) 
33/111 (29.7) 
 
 
NDMM: newly diagnosed MM; R-ISS: Revised-international staging system. 
 *Evaluated in patients with appropriate genetic risk assessed according to Sonneveld P, et al.,20 
when appropriate material was available.19 
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Supplementary Table 2. 
Patients characteristics, RRMM cohort. 
Variable N. patients (%) Median Values 
Median Age 201/201 (100) 62 years (54 - 69) 
Sex 
Male: 
Female:  
201/201 (100) 
129/201 (64.2) 
72/201 (35.8) 
 
R-ISS 
Stage I  
Stage II 
Stage III 
201/201 (100) 
61/201 (30.3) 
117/201 (58.2) 
23/201 (11.5) 
 
Type of MM 
IgG 
IgA 
IgM 
IgD 
Light chain 
Biclonal 
201/201 (100) 
124/201 (61.7) 
58/201 (28.8) 
3/201 (1.5) 
2/201 (1) 
13/201 (6.5) 
1/201 (0.5) 
 
Genetic risk*: 
Standard risk: 
High risk: 
183/201 (91) 
115/201 (62.8) 
68/201 (37.2) 
 
 
Hemoglobin 
Hb <10 g/dL 
201/201 (100) 
55/201 (27.4) 
10.2 g/dL (9.7 – 12.8) 
 
Kidney failure 
Yes: 
No: 
201/201 (100) 
64/201 (31.8) 
137/201 (68.2) 
 
Bone lesions 
Yes: 
No: 
201/201 (100) 
131/201 (65.2) 
70/201 (34.8) 
 
Extra medullary disease 
Yes: 
No: 
201/201(100) 
66 (32.8) 
135 (67.2) 
 
PD at sampling 105/201 (52.2)  
Previous transplant  
Yes: 
201/201 (100) 
149/201 (74.1) 
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No: 52/201 (25.9) 
IMiDs resistant 
Yes: 
No: 
201/201 (100) 
97/201 (48.3) 
104/201 (51.7) 
 
PI resistant 
Yes: 
No: 
201/201 (100) 
89/201 (44.3) 
112/201 (55.7) 
 
Previous Immunotherapy 16/201 (7.9)  
 
RRMM: relapsed/refractory MM; ISS: international staging system; PD: progressive disease; R-ISS: 
Revised-international staging system; IMiDs: immunomodulatory drugs; PI: proteasome inhibitor. 
*Evaluated in patients with appropriate genetic risk according to Sonneveld P, et al.20 when 
appropriate material was available21. PD: progressive disease, as defined by Rajikumar et al.5 
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Supplementary Table 3. Gene Expression profile summary comparison between survival 
characteristics from 646 patients divided in high- and low-expressers from CoMMpass 
longitudinal, prospective observational study (release IA12).  
 PFS OS 
Gene t-test; 
P value 
Fold 
change 
t-test; 
P value 
Fold 
change 
ENO-1  5.97; 
<.0001 
1.39 4.57 
<.0001 
1.43 
AURKA 5.31; 
<.0001 
1.87 4.11 
<.0001 
2 
VEGFA 4.63; 
<.0001 
1.31 2.43 
.02 
1.2 
JAM-A 2.29; 
0.02 
1.13 
 
2.64; 
<.01 
1.2 
TJP1 ns ns -2.59; 
<.01 
0.8 
 
PFS: progression free survival; OS: overall survival. ENO1: Enolase 1; AURKA: Aurora Kinase A; 
VEGFA: Vascular Endothelial Growth Factor A; JAM-A: Junctional adhesion molecule-A; TJP1: Tight 
junction protein-1. ns: not significant. 
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Supplementary Table 4. Primer sequences. 
Oligo Name Sequence 5' to 3' 
AURKA f GAAATTGGTCGCCCTC 
AURKA r TGATGAATTTGCTGTGATCC 
CASK f ATTCTCCATATCCATGTCTCCG 
CASK r TGGAAGAAATTTCATGTTACCC 
ENO-1 f GCCTCCTGCTCAAAGTCAAC 
ENO-1 r AACGATGAGACACCATGACG 
F11R f AAGTTGTCCTGTGCCTACTC 
F11R r ACCAGTTGGCAAGAAGGTCACC 
LFA1 f CACGAAGTTCAAGGTCAGCA 
LFA1 r TTGTGGTCTTCCTGGGTTTC 
MLLT4 f GCCAAGTGACAAAGGGAT 
MLLT4 r TAACTGAAGGCGGTAAAG 
TJP1 f TGCCTCCGAGAGAGATGACA 
TJP1 r CGCCAGCCACAAATATTCCG 
 
AURKA: Aurora Kinase A; LFA-1: Lymphocyte function-associated antigen 1;  CASK: 
Calcium/Calmodulin Dependent Serine Protein Kinase; ENO1: Enolase 1; F11R, alias for JAM-A, 
Junctional adhesion molecule-A; LFA-1: Lymphocyte function-associated antigen 1; MLLT4, alias 
for Afadin, Adherens Junction Formation Factor TJP1: Tight junction protein-1. 
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Supplementary Figure legends 
 
Supplementary Figure 1 
 
JAM-A is overexpressed in MM derived endothelial cells. (A) Basal mRNA expression 
level of JAM-A were detected in MMECs with real time RT-PCR. The mean of JAM-A mRNA 
expression levels in MGECs or in HUVECs were used as reference values and GAPDH as 
housekeeping gene. (B) Anti-CD34 and anti-JAM-A staining on a representative MGUS BM 
sample (compare to Figure 1D and main text for details). Magnification x 200, Scale bar=50 
μm. (C) Anti-CD31/anti-JAM-A double immunohistochemistry staining on BM trephine: 
within the control BM lacunae (see CD31+ megakaryocytes) the vessels are more distended 
and endothelia display a thin, uncospicuous cytoplasmic rim. CD31 (brown) highlights 
endothelia lining thin walled microvessels. Lumina appear to be only slightly dilated. Anti-
JAM-A (in red) stains a fraction of neoplastic plasma cells, with a cytoplasmatic pattern. 
Magnification x 200. Scale bar = 50 μm. Red insert: magnification x 2. (D) Absolute JAM-A 
expression across the entire cohort measured with flow cytometry and displayed as mean 
fluorescence intensity (MFI) values. (E) Kaplan Meier estimator of OS across the entire 
cohort recoded into quartiles of surface MMECs JAM-A expression levels. The median OS 
estimated in subjects within the lowest quartile (JAM-AQ1) MMECs cells at FACS was not 
reached whereas in subjects in the highest one (JAM-AQ4) MMECs the median OS was 88 
months (HR= 8.24, 95% CI 3.2–20.9, P< 0.0001; χ2LR=28.15; P< 0.0001 upper panel). Uni- 
and multivariate analysis (lower panel). BM: bone marrow; MMECs: BM primary MM 
endothelial cells; MGECs: MGUS derived endothelial cells; MFI: mean fluorescence 
intensity. 
 
Supplementary Figure 2 
 
Solimando et al.                 Supplementary Material 
 16 
Primary MM derived endothelial cells enhance sJAM-A levels and JAM-A-expression 
on MM after direct or indirect co-culture. Experimental designs depicted on the left. (A) 
MMECs directly co-cultured with RPMI-8226 cells at 1:5 ratio (RPMI8266:MMECs) or 
cultured alone for 24hrs. After removing tumor cells, MMECs were harvested and JAM-A 
post transcription level quantified using western blotting for RPMI-8226 cells. (B) MMECs 
cells were cultured alone or co-cultured with RPMI-8226 at 1:5 ratio (RPMI-8266:MMECs) 
directly co-cultured and MMECs cells analyzed for JAM-A expression with flow cytometry. 
(C) sJAM-A concentration was measured in MMECs CM with ELISA. Values represent 
mean ± SD. n = 12 for each group. sJAM-A concentration was measured in MM CM by 
ELISA. Values represent mean ± SD. n = 12 for each group; cells were directly co-cultured 
with RPMI-8226 cells at 1:5 ratio (RPMI8266:MMECs) or cultured alone for 24hrs. Co-
culture medium and medium of MMECs cultured alone were collected and sJAM-A 
concentration measured by ELISA. (D) OPM-2 cells were cultured alone or directly co-
cultured with MMECs at 1:5 ratio (OPM-2:MMECs) and analyzed for JAM-A expression by 
WB. Results are presented as mean ± SD (n=24 NDMM derived MMECs), Mann-Whitney 
test. *** P< .001; **** P< .0001. MMECs: bone marrow primary MM endothelial cells; CM: 
conditioned medium; NDMM: newly diagnosed MM. 
 
Supplementary Figure 3 
JAM-A neutralization impair MM endothelial cells function, without affecting MMECs 
viability. (A) Lack of anti-JAM-A-dependent induction of cytotoxicity against the MMECs 
measured with flow cytometry (Vivid, left panel). Cell viability did not differ in terms of % 
living cells from nine independent experiments, t-Student test. (B) Array of 55 human 
angiogenesis related proteins (left), and protein list analyzed. Relative mRNA expression 
level of PLG, ENO-1, FGF2, VEGFA, LFA-1, TJP1, CAV1, CASK, ADAM17, AURKA (C-L) 
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were investigated comparing MMECs to MGECs with real time RT-PCR to validate the 
proteome profiling results, (n=24 MGUS patients derived MGECs and 24 NDMM derived 
MMECs). Results are presented as mean ± SD, Mann-Whitney test. **** P< .0001. The 
mean of mRNA expression levels of JAM-A in HUVECs was used as reference sample and 
GAPDH as housekeeping gene. Graph compares the mRNA expression of each ligand 
between MGECs and MMECs and it shows the most expressed ligand in each cell type 
setting with the lower as unit. MMECs: bone marrow primary MM endothelial cells; PLG: 
plasminogen; ENO1: Enolase 1; FGF-2: Fibroblast growth factor-2; VEGFA: Vascular 
Endothelial Growth Factor A; LFA-1: Lymphocyte function-associated antigen 1; TJP1: Tight 
junction protein-1; CAV1: Caveolin1; CASK: Calcium/Calmodulin Dependent Serine Protein 
Kinase; ADAM17: ADAM metallopeptidase domain 17; AURKA: Aurora Kinase A; MGECs: 
MGUS derived endothelial cells; NDMM: newly diagnosed MM. See results and discussion 
for additional details.  
 
Supplementary Figure 4 
Effect of anti-JAM-A treatment on systemic sJAM-A, FGF2 and VEGF levels. (A) 
Representative extracted tumor masses after treatment from subcutaneous tumor xenograft 
model. (B) s-JAM-A (297,6 ± 15,57 and 71.89 ± 9,24 in the ISO Control and in the a-JAM-
A-treated group respectively, t-student test, P< .0001), (C) FGF-2 (median 1500 and 253.89 
in the ISO Control and in the a-JAM-A-treated group respectively, Mann-Whitney test, P< 
.0001) and (D) VEGF-A (42470 ± 2694 and 4070 ± 815,6 in the ISO Control and in the a-
JAM-A-treated group respectively, t-student test, P< .0001), significantly decreased in MM 
bearing mice after anti-JAM-A blocking antibody treatment, evaluated with ELISA. **** P< 
.0001. For one mouse there was not sufficient biological material for ELISA test available. 
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FGF-2: Fibroblast growth factor-2; VEGFA: Vascular Endothelial Growth Factor A; ISO: 
isotype control. 
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